CELL PhenomeX Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CELL

Price (delayed)

$1.16

Market cap

$83.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.42

Enterprise value

$39.75M

Berkeley Lights, Inc. operates as a biotechnology company. The Company provides technology solutions for single cell manipulation for biopharma, diagnostics, and life science research. Berkeley Lights serves customers worldwide.

Highlights
PhenomeX's debt has decreased by 3.5% YoY
The gross margin has increased by 3.3% YoY
The quick ratio has decreased by 47% YoY and by 26% QoQ
The company's net income fell by 37% YoY and by 13% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.berkeleylights.com
Peers: PKI PRPO MTD

Key stats

What are the main financial stats of CELL
Market
Shares outstanding
72.17M
Market cap
$83.72M
Enterprise value
$39.75M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.56
Price to sales (P/S)
1.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.51
Earnings
Revenue
$78.6M
EBIT
-$97.03M
EBITDA
-$84.91M
Free cash flow
-$55.62M
Per share
EPS
-$1.42
Free cash flow per share
-$0.81
Book value per share
$2.07
Revenue per share
$1.14
TBVPS
$3.28
Balance sheet
Total assets
$226.09M
Total liabilities
$84.04M
Debt
$42.55M
Equity
$142.06M
Working capital
$131.46M
Liquidity
Debt to equity
0.3
Current ratio
3.89
Quick ratio
3.33
Net debt/EBITDA
0.52
Margins
EBITDA margin
-108%
Gross margin
68.4%
Net margin
-124.7%
Operating margin
-124.8%
Efficiency
Return on assets
-40.2%
Return on equity
-58.7%
Return on invested capital
-78.1%
Return on capital employed
-53.7%
Return on sales
-123.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CELL stock price

How has the PhenomeX stock price performed over time
Intraday
-4.13%
1 week
-3.33%
1 month
-29.7%
1 year
-83.5%
YTD
-56.72%
QTD
-56.72%

Financial performance

How have PhenomeX's revenue and profit performed over time
Revenue
$78.6M
Gross profit
$53.78M
Operating income
-$98.05M
Net income
-$98.04M
Gross margin
68.4%
Net margin
-124.7%
The operating margin has dropped by 51% year-on-year and by 22% since the previous quarter
PhenomeX's net margin has decreased by 48% YoY and by 21% QoQ
The company's operating income fell by 39% YoY and by 14% QoQ
The company's net income fell by 37% YoY and by 13% QoQ

Growth

What is PhenomeX's growth rate over time

Valuation

What is PhenomeX stock price valuation
P/E
N/A
P/B
0.56
P/S
1.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.51
PhenomeX's EPS has decreased by 31% YoY and by 10% QoQ
CELL's price to book (P/B) is 67% lower than its last 4 quarters average of 1.7
The company's equity fell by 32% YoY and by 10% QoQ
The price to sales (P/S) is 71% lower than the last 4 quarters average of 3.5
The company's revenue fell by 8% YoY and by 6% QoQ

Efficiency

How efficient is PhenomeX business performance
PhenomeX's return on equity has shrunk by 85% YoY and by 25% QoQ
PhenomeX's return on assets has shrunk by 66% YoY and by 20% QoQ
PhenomeX's return on sales has decreased by 49% YoY and by 21% QoQ
CELL's return on invested capital is down by 10% since the previous quarter and by 8% year-on-year

Dividends

What is CELL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CELL.

Financial health

How did PhenomeX financials performed over time
CELL's total assets is 169% greater than its total liabilities
The quick ratio has decreased by 47% YoY and by 26% QoQ
PhenomeX's current ratio has decreased by 45% YoY and by 26% from the previous quarter
PhenomeX's debt is 70% lower than its equity
CELL's debt to equity is up by 43% year-on-year and by 11% since the previous quarter
The company's equity fell by 32% YoY and by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.